CDK5 and Alzheimer disease: Thereafter, TFP5 (modified as P5) was designed to penetrate the blood–brain barrier after intraperitoneal injections, which inhibited abnormal Cdk5/p25 hyperactivity and significantly rescued AD pathology in AD model mice (Shukla et al., 2013).